The results demonstrated that the combination of anti-IL-16 antibodies with MLN8237 results in decreased tumor growth (Fig. 7E), augmented infiltration of CD8+ T cells, and reduced infiltration of CD4+ T cells (Fig. 7F–J). This evidence concerns the gene IL16 and neoplasm.